<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889653</url>
  </required_header>
  <id_info>
    <org_study_id>16ek0210055h</org_study_id>
    <secondary_id>000023669</secondary_id>
    <nct_id>NCT02889653</nct_id>
  </id_info>
  <brief_title>The Bleeding With Antithrombotic Therapy Study 2</brief_title>
  <acronym>BAT2</acronym>
  <official_title>The Bleeding With Antithrombotic Therapy Study 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cerebral and Cardiovascular Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the incidence and severity of bleeding
      complications in patients with cerebrovascular and cardiovascular diseases treated with oral
      antithrombotic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>ISTH major bleeding</measure>
    <time_frame>within 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non-major bleeding</measure>
    <time_frame>within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic event details</measure>
    <time_frame>within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events and those details</measure>
    <time_frame>within 2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Cerebrovascular and Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Any oral antithrombotics (antiplatelets or anticoagulants)</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cerebrovascular or cardiovascular diseases who start or continue taking oral
        antithrombotics (antiplatelets and/or anticoagulants) to prevent vascular events in
        participating centers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cerebrovascular or cardiovascular diseases who start or continue taking
             oral antithrombotics (antiplatelets and/or anticoagulants) to prevent vascular events

          -  Patients who are able to receive MRI

          -  Provision of written informed consent either directly or by a suitable surrogate

        Exclusion Criteria:

          -  MRI contraindication

          -  Any condition that in the opinion of the responsible physician or investigator that
             renders the patient unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shoichiro Sato, MD, PhD</last_name>
    <phone>+81-6-6833-5012</phone>
    <email>bat2@ncvc.go.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5658565</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shoichiro Sato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasushi Okada</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Marianna University</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuhiro Hasegawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuyuki Sakai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Okuda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saga University</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yusuke Yakushiji</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokushima University</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shinji Nagahiro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Daida</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyorin University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teruyuki Hirano</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://bat2.stroke-ncvc.jp</url>
  </link>
  <results_reference>
    <citation>Yasaka M, Brainsky A, Toyoda K. Prothrombin Complex Concentrate for Vitamin K Antagonist-Associated Intracranial Hemorrhage - Global Evidence and the Japanese Perspective. Circ J. 2017 Oct 25;81(11):1564-1573. doi: 10.1253/circj.CJ-17-0428. Epub 2017 Jul 19.</citation>
    <PMID>28724836</PMID>
  </results_reference>
  <results_reference>
    <citation>Koga M, Yoshimura S, Hasegawa Y, Shibuya S, Ito Y, Matsuoka H, Takamatsu K, Nishiyama K, Todo K, Kimura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Kameda T, Nagakane Y, Yagita Y, Kario K, Shiozawa M, Sato S, Yamagami H, Arihiro S, Toyoda K; SAMURAI Study Investigators. Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation. Stroke. 2016 Oct;47(10):2582-8. doi: 10.1161/STROKEAHA.116.013746. Epub 2016 Aug 16.</citation>
    <PMID>27531346</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cerebral and Cardiovascular Center</investigator_affiliation>
    <investigator_full_name>Kazunori Toyoda</investigator_full_name>
    <investigator_title>Director and Chair, Department of Stroke and Cerebrovascular Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

